|
KMID : 0043320190420060481
|
|
Archives of Pharmacal Research
2019 Volume.42 No. 6 p.481 ~ p.491
|
|
|
Targeting ROCK/LIMK/cofilin signaling pathway in cancer
|
|
Lee Mee-Hyun
Kundu Joydeb Kumar
Chae Jung-Il
Shim Jung-Hyun
|
|
|
Abstract
|
|
|
|
Rho-associated coiled-coil-containing protein kinase (ROCK)/Lin11, Isl-1 and Mec-3 kinase (LIMK)/cofilin-signaling cascades are stimulated by receptor tyrosine kinases, G protein-coupled receptors, integrins and its ligands, growth factors, hormones, fibronectin, collagen, and laminin. Activated signaling cascades can cause transit from normal cells to cancer cells by modulating actin/filament dynamics. In various cancers including breast, prostate, and colorectal cancers, high expression or activity of each cascade protein is significantly associated with poor survival rate of patients as well as aggressive metastasis. Silencing ROCK, LIMK, or cofilin can abrogate their activities and inhibit cancer cell growth, invasion, and metastasis. Therefore ROCK/LIMK/cofilin signaling proteins might be good candidates to develop cancer prevention strategies or therapeutics. Currently, netarsudil, a ROCK inhibitor, is only used in clinical patients for glaucoma or ocular hypertension, but not for cancer. In this review, we will discuss comprehensive ROCK/LIMK/cofilin signaling pathway in cancers and its inhibitors for developing cancer therapy.
|
|
|
KEYWORD
|
|
|
ROCK, LIMK, Cofilin, Signaling pathways, Inhibitors, Cancer therapy
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|
|